Company Performance Metrics
- Karl Kieburtz: Chief Medical Officer
- Kent Savage: President & CEO
PhotoPharmics is a clinical-stage therapeutic device company developing next-generation treatments for addressing neurodegenerative disorders through the eyes. We have 30 years of experience in product innovation, clinical trials, and market development in specialized phototherapy. We previously developed specialized solutions now widely used to
regulate circadian rhythms for seasonal affective disorder, sleep disorders, anxiety, and depression (acquired by Philips-Respironics in 2007).
Our main focus is Parkinson’s, and we are extending our research into several other neurodegenerative diseases. We aim to make a clinically meaningful difference in patients’ lives by delivering safe and effective treatments. PhotoPharmics is privately held and is raising a Series B equity round to fund the Celeste Light for Parkinson’s pivotal trial.
